Samaritan Expands Revenue Opportunities with Marketing Authorization Approval for HIV Drug Amphocil in Cyprus

Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health... - January 03, 2008 - Samaritan Pharmaceuticals

Actors Studio's Anna Strasberg Joins Samaritan Advisory Board of Directors

Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals

Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus

Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals

EUSA Pharma Signs Exclusive Distribution Agreement with Samaritan for Anesthetic Pain Patch to Launch and Sell in Greece and Cyprus

Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals

Survey Verifies Link Between Nurses' Illness and Occupational Exposure

Scientists recently released the results of the first ever national survey which assessed nurses’ extent and frequency of exposures to common health care hazards. - December 19, 2007 - Carmel Pharma

Cardiovascular Sciences, Inc. Announces Funding Event

Cardiovascular Sciences, Inc. Announces Funding Event

Cardiovascular Sciences, Inc. (CVSC), a corporation under the laws of Nevada, is excited to reveal an initial funding event with Seven Palm Investments, LLC of Illinois. After a recent assessment and restructuring of the company’s equity, the company and its investors are ready to move ahead... - December 12, 2007 - Cardiovascular Sciences, Inc.

Carmel Pharma Introduces the Next Evolution of PhaSeal

Today, Carmel Pharma, Inc. introduces the Injector Luer Lock N35 with ErgoMotion™ during the 42nd ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV. - December 03, 2007 - Carmel Pharma

Samaritan Presented Favorable Caprospinol Data at Alzheimer's Drug Development Summit

In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals

Live Continuing Education for Pharmacists on the Safe Handling of Hazardous Drugs

Carmel Pharma, manufacturer and distributor of PhaSeal, announced that they are sponsoring a live, accredited continuing education (CE) seminar during this year’s 42nd Annual ASHP Midyear Clinical Meeting and Exhibition in Las Vegas, NV in December. - November 09, 2007 - Carmel Pharma

World-Renowned Physician and HIV Researcher Joins Samaritan's Advisory Board

Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals

Samaritan Licenses Tumor Inhibiting Cancer Drugs That Also Distinguish Cancerous Tumors to Improve on Chemotherapy

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

Samaritan Licenses Method to Identify Novel Anti-Tumor Drugs to Increase Cancer Compounds in Pipeline

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

Aerotrim Wins £3.9M Order from UK MoD

Aerotrim (Warminster) Ltd has secured a £3.9M order for manufacturing insulation lining for MoD tentage used in field operations. - August 04, 2007 - Aerotrim Group

New Research Presented by MD Anderson and University of Utah Verifies Dry Connections with PhaSeal

New evidence-based research was presented at ONS Congress by MD Anderson and the University of Utah which concluded only the PhaSeal System confined the drug, thus proving the prevention of drug exposure from preparation through administration of hazardous drugs. - May 05, 2007 - Carmel Pharma

Carmel Pharma, Inc. Launches New PhaSeal Preparation Component

Carmel Pharma, Inc. launches their new Protector 28 (P28). This preparation component is the latest advancement of the PhaSeal System and is available now. - May 03, 2007 - Carmel Pharma

Carmel Pharma Offers New Continuing Education Program

Carmel Pharma, manufacturers and distributors of PhaSeal, announced today that they are now offering an accredited continuing education (CE) program developed by STAT Educational Services, an accredited provider of continuing education for various healthcare professionals. - April 25, 2007 - Carmel Pharma

New Evidence-based Research will be Unveiled During 'Ask the Experts’ at ONS Congress in April

New evidence-based research for determining adherence to the NIOSH definition of a closed-system will be unveiled during ‘Ask the Experts’ at the ONS Congress on Wednesday, April 25 in Las Vegas, NV. ‘Ask the Experts’ will be held from 1pm-2pm on Wednesday, April 25 in the... - April 04, 2007 - Carmel Pharma

Blue Sky Biotech, Inc Appoints Scott Gridley, Ph.D., as Senior Research Scientist

Blue Sky Biotech, Inc. announced the June 1st appointment of Scott Gridley, Ph.D., as Senior Research Scientist. Dr. Gridley previously worked for five years in the metabolic diseases division of Sandoz Research Institute (now Novartis Institutes for BioMedical Research) where he was involved in... - August 15, 2006 - Blue Sky Biotech, Inc.

Blue Sky Biotech, Inc Names Dr. Norman Garceau, Former Scientist at Pfizer Global Research and Development, as Chief Scientific Officer

Blue Sky Biotech, Inc. announced the Feb 1st appointment of Norman Garceau, Ph.D., as Chief Scientific Officer. Dr. Garceau previously worked in early drug discovery at the Pfizer Research Technology Center (Cambridge, MA) from 1999 to 2006, engaged in a range of activities that included gene cloning and expression profiling, cell biology, assay development, and lead discovery. - March 15, 2006 - Blue Sky Biotech, Inc.

Hovione Expands its Range of Services in Particle Design Technology

Hovione has increased its range of services and multi-scale facilities in cGMP Spray Drying, an advanced particle design technology. Building on its accumulated expertise in all major areas of API development and cGMP manufacture, a full range of cGMP Spray Drying facilities operating at lab, pilot and industrial scale have now been installed at Hovione's API manufacturing plant in Europe and are currently being installed at Hovione’s Technology Transfer Centre in New Jersey, USA. - August 26, 2005 - Hovione

Press Releases 201 - 220 of 220